Actively Recruiting
Contribution of Multiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions Whose Malignant Origin Cannot be Excluded on Conventional Imaging
Led by Central Hospital, Nancy, France · Updated on 2025-01-08
68
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of non-invasive Single Photon Emission Computed Tomography combined with CT (SPECT-CT) bone scintigraphy to better characterize solitary bone lesions. The study aims to determine if this imaging method can help exclude malignancy and reduce the need for biopsies and related complications. This approach builds on previous findings that malignant bone lesions show increased activity at all three stages of bone scintigraphy but lacked precise anatomical localization on planar images. The study involves a bone scan procedure with three stages: perfusion study, early tissue uptake, and late bone fixation. Participants with indeterminate solitary bone lesions scheduled for biopsy or excision will undergo the multiparametric analysis using SPECT-CT. The imaging will quantify signal intensity (SUVmax) at each stage to assess lesion nature. This analysis may improve classification of solitary bone lesions compared to conventional imaging. Participants will undergo the bone scintigraphy and have their lesions analyzed using multiple parameters, including Time To Peak and Standard Uptake Value max at early and late stages. Researchers will measure the diagnostic performance of these parameters within 24 hours. The study includes informed consent, social security affiliation, and assessments of safety and exclusion factors such as pregnancy and allergies to the radiopharmaceutical. The trial period extends until January 2027.
CONDITIONS
Brief Title
Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Person, having received complete information on the organization of the research and having signed the informed consent
- Age 18 years or older
- Having read and understood the information document
- Affiliated to a social security scheme
- Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy or excision is planned
You will not qualify if you...
- Pregnant woman or woman of childbearing age without contraceptive means or nursing mother
- Unstable medical condition or inability to remain still during recordings
- Known allergy to the radiopharmaceutical technetium-99m-Technescan HDP
- Person deprived of liberty by judicial or administrative decision
- Person subject to psychiatric care under relevant legal articles
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo bone scintigraphy consisting of three stages: perfusion study, early tissue uptake, and late bone fixation to analyze solitary bone lesions.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
CHRU Nancy
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Research Team
A
ACHRAF BAHLOUL, MD, MSc
V
VERONIQUE ROCH, MSc
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here